Clinical trial NCT06801743: WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS
Official title: WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Premature Ventricular Complexes
Ventricular Arythmias
Cardiac Magnetic Resonance Imaging
Focal or Diffuse Fibrosis
Structural Heart Disease
Idiopathic
Keywords: premature ventricular complexes
ventricular arythmias
cardiac magnetic resonance
focal or diffuse fibrosis
structural heart disease
idiopathic
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2025-01-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with PVC who have performed ECG, Holter ECG and a CMR

Brief summary: Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope.

The initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or "idiopathic" ventricular arrhythmias (IVA).

However, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies.

Cardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC.

However, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa).

This study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.


Eligibility criteria: Inclusion Criteria:

* patients with PVC who have performed ECG, Holter ECG and a CMR

Exclusion Criteria:

* patient showing opposition tu use his personal data for the reseach,
* patient unable to express his opposition,
* patient deprived of liberty,
* patient with language issues (speaking or writing French)

Primary outcomes:
measure: Number of myocardial abnormalities identified by CMR
timeFrame: 1 day
Secondary outcomes:
measure: number of criteria to predict myocardial abnormalities on CMR
timeFrame: day 1
Other outcomes:
Locations:
city: Salouel
country: France
facility: Centre Hospital-Universitaire d'Amiens
Study officials:
References: